Slayback Gets PTAB To Wipe Out Schizophrenia Treatment IP
The Patent Trial and Appeal Board has invalidated dozens of claims in a Sumitomo Dainippon Pharma patent for treating schizophrenia without certain side effects, finding that the claims were obvious....To view the full article, register now.
Already a subscriber? Click here to view full article